HomeInsightsPE

Shukra Pharmaceuticals Ltd P/E Ratio

Shukra Pharmaceuticals Ltd P/E Ratio

download
stocks purchased

₹ 1.2 Cr

Volume transacted

stocks purchased

148.3 K

stocks traded

Last Updated time: 25 Jul 10:05 AM

Image

Shukra Pharmaceuticals Ltd

NSE: SHUKRAPHARMA

PE

19.5

Last updated : 25 Jul 10:05 AM

Key Highlights

    The P/E Ratio of Shukra Pharmaceuticals Ltd is 19.5 as of 25 Jul 10:05 AM .a1#The P/E Ratio of Shukra Pharmaceuticals Ltd changed from 12.4 on March 2019 to 4.2 on March 2023 . This represents a CAGR of -19.47% over 5 years. a1#The Latest Trading Price of Shukra Pharmaceuticals Ltd is ₹ 82.55 as of 24 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 5.72 crore on March 2019 to ₹ 18.08 crore on March 2023 . This represents a CAGR of 25.88% over 5 years. a1#The Revenue of Shukra Pharmaceuticals Ltd changed from ₹ 6.57 crore to ₹ 12.26 crore over 8 quarters. This represents a CAGR of 36.60% a1#The EBITDA of Shukra Pharmaceuticals Ltd changed from ₹ 0.96 crore to ₹ 5.81 crore over 8 quarters. This represents a CAGR of 146.01% a1#The Net Pr of Shukra Pharmaceuticals Ltd changed from ₹ 0.33 crore to ₹ 3.99 crore over 8 quarters. This represents a CAGR of 247.72% a1#The Dividend Payout of Shukra Pharmaceuticals Ltd changed from 17.07 % on March 2019 to 4.43 % on March 2023 . This represents a CAGR of -23.65% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Shukra Pharmaceuticals Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Shukra Pharmaceuticals Ltd

Period
Mar '1912.4
Mar '20203.3
Mar '2137.1
Mar '2212.6
Mar '234.2

Company Fundamentals for Shukra Pharmaceuticals Ltd

Market Cap

361 Cr

EPS

4.2

P/E Ratio (TTM) *

19.5

P/B Ratio (TTM) *

6.3

Day’s High

82.55

Day’s Low

79.35

DTE *

0.1

ROE *

32.2

52 Week High

129.9

52 Week Low

20.43

ROCE *

33.1

* All values are consolidated

Last Updated time: 25 Jul 10:05 AM

* All values are consolidated

Last Updated time: 25 Jul 10:05 AM

Image

Shukra Pharmaceuticals Ltd

NSE: SHUKRAPHARMA

PRICE

82.55

1.60 (1.98%)

stock direction

Last updated : 24 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Shukra Pharmaceuticals Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value of Shukra Pharmaceuticals Ltd

Market Value

361

Asset Value

53

5.8 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Shukra Pharmaceuticals Ltd19361
Sun Pharmaceuticals Industries Ltd38388,632
Cipla Ltd28121,443
Divis Laboratories Ltd75120,718
Zydus Lifesciences Ltd30118,680
Dr Reddys Laboratories Ltd20113,730

Key Valuation Metric of Shukra Pharmaceuticals Ltd

Earnings

18 Cr

19.5 X

PE Ratio

Market Cap

₹361.47Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

18 Cr

19.5 X

PE Ratio

Market Cap

₹361.47Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Shukra Pharmaceuticals Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Shukra Pharmaceuticals Ltd

Period
Mar '196
Mar '207
Mar '217
Mar '229
Mar '2318

* All values are a in crore

×

Historical Revenue of Shukra Pharmaceuticals Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Shukra Pharmaceuticals Ltd

Period
Jun '227
Sep '224
Dec '223
Mar '2347
Jun '2321
Sep '2325
Dec '2319
Mar '2412

* All values are a in crore

×

Historical EBITDA of Shukra Pharmaceuticals Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Shukra Pharmaceuticals Ltd

Period
Jun '221
Sep '221
Dec '221
Mar '235
Jun '231
Sep '235
Dec '2310
Mar '246

* All values are a in crore

×

Historical Net Profit of Shukra Pharmaceuticals Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Shukra Pharmaceuticals Ltd

Period
Jun '220
Sep '220
Dec '220
Mar '234
Jun '230
Sep '235
Dec '239
Mar '244

* All values are a in crore

×

Historical Dividend Payout of Shukra Pharmaceuticals Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Shukra Pharmaceuticals Ltd

Period
Mar '1917
Mar '200
Mar '210
Mar '2210
Mar '234

* All values are a in %

About Shukra Pharmaceuticals Ltd

About Shukra Pharmaceuticals Ltd

    Shukra Pharmaceuticals Ltd (Formerly known Relish Pharmaceuticals Limited) was established in March 1993 and later on the name of Company got changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on 22 September, 2016. The Company is presently engaged in the business of manufacturing of pharmaceuticals Products and laboratory testing. The company provides varieties of products to the clientele. Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others. The company has four manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental. Their manufacturing unit is located at Rakanpur in Gujarat. The company customers include leading Manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, Agenta Pharma Limited etc. The company has assisted in the development and manufacture of a wide variety of drugs and dosage forms and potency variations for many prestigious pharmaceuticals companies around the world. In FY 2013-14, the Company got approval from Hon'ble High Court of Gujarat for revival of Relish Pharmaceuticals Limited and Amalgamation of Proper Dealcomm Private Limited (Transferor Company) with Relish Pharmaceuticals Limited (Transferee Company) and Re-organization of Share Capital of Relish Pharmaceuticals Limited (Transferee Company) through Scheme of Arrangement vide Hon'ble High Court of Gujarat order dated 20 Dec' 2013.

Shukra Pharmaceuticals Ltd News Hub

News

Board of Shukra Pharmaceuticals recommends final dividend

Shukra Pharmaceuticals announced that the Board of Directors of the Company at its meeting...

Read more

30 May 202412:16

News

Shukra Pharmaceuticals to announce Quarterly Result

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 ...

Read more

21 May 202413:01

News

Board of Shukra Pharmaceuticals allots 3.28 cr bonus shares

The Board of Shukra Pharmaceuticals at its meeting held on 25 April 2024 has allotted 3,28...

Read more

25 Apr 202420:01

News

Shukra Pharmaceuticals schedules board meeting

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 ...

Read more

18 Mar 202416:09

News

Shukra Pharmaceuticals to conduct board meeting

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 ...

Read more

24 Feb 202412:19

News

Shukra Pharmaceuticals to discuss results

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 ...

Read more

05 Feb 202419:15

Product Composition by Percentage (Revenue)

FAQs for PE of Shukra Pharmaceuticals Ltd

What is Shukra Pharmaceuticals Ltd current share price?

The current market price of Shukra Pharmaceuticals Ltd as of July 25, 2024 is ₹82.55.

What is Shukra Pharmaceuticals Ltd's market cap?

Shukra Pharmaceuticals Ltd's market capitalisation stood at ₹361 Cr as of July 25, 2024

What are Shukra Pharmaceuticals Ltd's total net assets?

According to Shukra Pharmaceuticals Ltd's most recent financial filings, the company's net assets total ₹53.1 Cr.

Is Shukra Pharmaceuticals Ltd making a profit or loss?

Shukra Pharmaceuticals Ltd's net Profit as of July 25, 2024 is close to ₹18 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199